Navigation Links
Human neural stem cells restore motor function in mice with chronic spinal cord injury
Date:8/19/2010

Irvine, Calif., Aug. 19, 2010 A UC Irvine study is the first to demonstrate that human neural stem cells can restore mobility in cases of chronic spinal cord injury, suggesting the prospect of treating a much broader population of patients.

Previous breakthrough stem cell studies have focused on the acute, or early, phase of spinal cord injury, a period of up to a few weeks after the initial trauma when drug treatments can lead to some functional recovery.

The UCI study, led by Aileen Anderson and Brian Cummings of the Sue & Bill Gross Stem Cell Research Center, is significant because the therapy can restore mobility during the later chronic phase, the period after spinal cord injury in which inflammation has stabilized and recovery has reached a plateau. There are no drug treatments to help restore function in such cases.

The study appears in the open-access, peer-reviewed journal PLoS ONE and is available online at http://dx.plos.org/10.1371/journal.pone.0012272.

The Anderson-Cummings team transplanted human neural stem cells into mice 30 days after a spinal cord injury caused hind-limb paralysis. The cells then differentiated into neural tissue cells, such as oligodendrocytes and early neurons, and migrated to spinal cord injury sites. Three months after initial treatment, the mice demonstrated significant and persistent recovery of walking ability in two separate tests of motor function when compared to control groups.

"Human neural stem cells are a novel therapeutic approach that holds much promise for spinal cord injury," said Anderson, associate professor of physical medicine & rehabilitation and anatomy & neurobiology at UCI. "This study builds on the extensive work we previously published in the acute phase of injury and offers additional hope to those who are paralyzed or have impaired motor function."

"About 1.3 million individuals in the U.S. are living with chronic spinal cord injury," added Cummings, associate professor of physical medicine & rehabilitation and anatomy & neurobiology. "This latest study provides additional evidence that human neural stem cells may be a viable treatment approach for them."

The research is the latest in a series of collaborative studies conducted since 2002 with StemCells Inc. that have focused on the use of StemCells' human neural stem cells in spinal cord injury and resulted in multiple co-authored publications. StemCells Inc., based in Palo Alto, Calif., is engaged in the research, development and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery.

According to Dr. Stephen Huhn, vice president and head of the central nervous system program at StemCells Inc., "the strong preclinical data we have accumulated to date will enable our transition to a clinical trial, which we plan to initiate in 2011."


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Input-output trade-offs found in human information processing
2. Human Meds Are Pets Biggest Poisoning Danger
3. NIH launches effort to define markers of human immune responses
4. New human adenovirus may not make for good vaccines, after all
5. Human clinical trial of NIH-developed dengue vaccine begins
6. Human embryonic stem cells purified in new, rapid technique
7. Scientists develop the first model for investigating the origins of testicular cancer in humans
8. Scientists unravel human-ecosystem interactions
9. UCLA scientists for the first time identify a cell-of-origin for human prostate cancer
10. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
11. Non-human sugar in biotech drugs causes inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... The JPR Group, a ... announce that it will be assisting HackensackUMC Mountainside with its public relations efforts, ... servicing all surrounding towns. The firm will be working closely with HackensackUMC Mountainside’s ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... frame transition from one clip to the next. , To use “Cut-Out First” ...
(Date:1/13/2017)... NJ (PRWEB) , ... January 13, 2017 , ... ... sale companions, will be showcasing the next generation companion scanner and data collector at ... The new KDC270 has been created as an answer to the market’s need for ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... 2017 , ... MyGenetx, a molecular laboratory headquartered in middle Tennessee is proud ... Smith, RD, LD, will serve on the 2017 TBCC Board. , Kris ... and one year as Vice President. She will oversee the newly elected board of ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017  Rosen ... the filing of a class action lawsuit on behalf ... ALXN ) from February 10, 2014 through November ... to recover damages for Alexion investors under the federal ... action, go to http://rosenlegal.com/cases-991.html or call ...
(Date:1/13/2017)... , Jan. 13, 2017 Over the last 10 years ... rapidly (6% – 10% yoy) and are expected to deliver remarkable future ... region, followed by Thailand , the Philippines ... and Singapore .  A member of the G20 and ... almost 40% of the SEA,s economic output and the largest pharma manufacturing ...
(Date:1/13/2017)... -- ... Research and Markets has announced the addition of the ... offering. The disease is divided into two categories ... melanoma, which can be treated with surgery, and advanced melanoma, which ... therapy aiming to prevent disease re-occurrence, and advanced therapies aiming to ...
Breaking Medicine Technology: